LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $9 Price Target 8/22/2024 10:55:20 PM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $99 Price Target 8/8/2024 5:07:03 PM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $99 Price Target 7/22/2024 5:07:53 PM
  • Nuvalent Doses First Patient In HEROEX-1 Phase 1a/1b Clinical Trial Of NVL-330 7/22/2024 6:33:52 AM
  • Nuvalent Names Henry Pelish As Chief Scientific Officer 7/11/2024 6:33:44 AM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $99 Price Target 6/21/2024 8:07:55 AM
  • Wedbush Is Lowering Nuvalent, Inc. (NUVL) FY24 Estimate To -3.01 From -2.99 5/9/2024 5:01:32 PM
  • Wedbush Is Increasing Nuvalent, Inc. (NUVL) Q4 24 Estimate To -0.82 From -0.85 5/9/2024 5:01:18 PM
  • Wedbush Is Raising Nuvalent, Inc. (NUVL) Q3 24 Estimate To -0.78 From -0.79 5/9/2024 5:01:05 PM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $99 Price Target 5/9/2024 5:00:33 PM
  • Nuvalent Q1 Loss Widens 5/9/2024 9:27:23 AM
  • Nuvalent Q1 Loss/shr Widens To $0.69 From $0.44 Last Year 5/9/2024 7:21:27 AM
  • Wedbush Reiterates Nuvalent, Inc. (NUVL) At Outperform With $99 Price Target 2/27/2024 5:05:44 PM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap